Valuation: 4basebio PLC

Market Cap 82.35M 110M 98.81M 90.89M 154M 10.48B 157M 1.08B 435M 5.51B 414M 405M 17.38B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 86.95M 116M 104M 95.97M 163M 11.06B 166M 1.14B 459M 5.82B 437M 428M 18.35B EV / Sales 2026 *
82.8x
EV / Sales 2027 * 21.9x
Free-Float
38.75%
Yield 2026 *
-
Yield 2027 * -
1 week+0.95%
1 month-5.78%
3 months+0.95%
6 months+4.95%
Current year-13.82%
1 week 500
Extreme 500
560
1 month 495
Extreme 495
575
Current year 420
Extreme 420
630
1 year 420
Extreme 420
820
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 09/02/2026
Chief Tech/Sci/R&D Officer - 28/02/2025
Chief Operating Officer - 11/03/2026
Director TitleAgeSince
Director/Board Member 48 21/12/2020
Director/Board Member 33 07/08/2024
Chairman 60 07/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Buy

Chief Executive Officer

1,863 0.0120%
16/02/26 Buy

Chief Executive Officer

2,650 0.0171%
11/02/26 Buy

Director

3,000 0.0193%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.95%-32.91%+2.91% 110M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.31%+6.88%+39.53%+175.78% 39.45B
Weighted average by Cap. +0.18%+5.44%+47.97%+176.62%

Financials

2026 *2027 *
Net sales 1.05M 1.41M 1.26M 1.16M 1.96M 134M 2M 13.82M 5.55M 70.26M 5.28M 5.17M 222M 5M 6.7M 6M 5.52M 9.35M 636M 9.52M 65.81M 26.42M 335M 25.14M 24.6M 1.06B
Net income -18.2M -24.38M -21.84M -20.09M -34.02M -2.32B -34.66M -240M -96.16M -1.22B -91.5M -89.56M -3.84B -
Net Debt 4.6M 6.16M 5.52M 5.08M 8.6M 585M 8.76M 60.54M 24.3M 308M 23.13M 22.64M 971M 27.1M 36.31M 32.52M 29.91M 50.66M 3.45B 51.6M 357M 143M 1.81B 136M 133M 5.72B
Projected Income Statement - Annual - 4basebio PLC
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
30/10/26 GBX 530.00 -.--% 112
29/10/26 GBX 530.00 -.--% 1,480
28/10/26 GBX 530.00 -.--% 137
27/10/26 GBX 530.00 -.--% 325
26/10/26 GBX 530.00 +0.95% 3,679
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - 4basebio PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.300GBP
Average target price
12.25GBP
Spread / Average Target
+131.13%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - 4basebio PLC